Motley Fool Asset Management LLC Acquires 150 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Motley Fool Asset Management LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,565 shares of the company’s stock after buying an additional 150 shares during the period. Motley Fool Asset Management LLC’s holdings in IDEXX Laboratories were worth $1,424,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Blair William & Co. IL increased its stake in shares of IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock worth $524,700,000 after purchasing an additional 7,812 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of IDEXX Laboratories by 2.2% in the third quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock valued at $507,725,000 after buying an additional 24,741 shares during the last quarter. Morgan Stanley boosted its stake in shares of IDEXX Laboratories by 4.7% during the 3rd quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock worth $465,482,000 after acquiring an additional 48,095 shares during the period. Northern Trust Corp increased its holdings in shares of IDEXX Laboratories by 7.7% during the 3rd quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock worth $401,935,000 after acquiring an additional 65,891 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in IDEXX Laboratories by 1.4% in the 3rd quarter. Principal Financial Group Inc. now owns 815,863 shares of the company’s stock valued at $356,753,000 after acquiring an additional 11,315 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several research reports. The Goldman Sachs Group upped their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Barclays boosted their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a research note on Tuesday, January 30th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $10.06 during trading hours on Friday, hitting $499.30. 529,811 shares of the company were exchanged, compared to its average volume of 431,856. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a market cap of $41.47 billion, a price-to-earnings ratio of 49.58, a P/E/G ratio of 3.81 and a beta of 1.26. The firm’s fifty day moving average is $531.02 and its 200 day moving average is $510.75.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock valued at $24,871,960 over the last three months. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.